Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus MINIPRESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus MINIPRESS.
FLOMAX vs MINIPRESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker